Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (181-190 of 383) with videos related to

Pageof 39
Sort By:
Breast (Edinburgh, Scotland)|February 19, 2013
Triple negative breast cancer: clinical characteristics in the different histological subtypesGeertje Dreyer, Thijs Vandorpe, Ann Smeets, et al.
Plos One|March 4, 2014
A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samplesMelike Marsan, Gert Van den Eynden, Ridha Limame, et al.
Radiology and Oncology|January 23, 2020
Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot studyBrigitte Maximiliana Aarts, Elisabeth Geneviève Klompenhouwer, Raphaëla Carmen Dresen, et al.
Plos One|April 6, 2012
A mathematical model for interpretable clinical decision support with applications in gynecologyVanya M C A Van Belle, Ben Van Calster, Dirk Timmerman, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2015
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08Khalil Zaman, Ralph Winterhalder, Christoph Mamot, et al.
The Breast Journal|November 13, 2010
Additional value of PET-CT in staging of clinical stage IIB and III breast cancerIsabelle Segaert, Felix Mottaghy, Sarah Ceyssens, et al.
Breast Cancer Research : BCR|August 24, 2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, Hope S Rugo, Sara M Tolaney, et al.
Obstetrics and Gynecology|May 4, 2004
Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX studyPatrick Neven, Deborah Quail, Marc Lévrier, et al.
BMC Medical Genomics|July 4, 2009
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trialChristine Desmedt, Anita Giobbie-Hurder, Patrick Neven, et al.
BMC Pharmacology & Toxicology|April 17, 2015
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerSandrina Lambrechts, Diether Lambrechts, Evelyn Despierre, et al.
Pageof 39

Showing results (181-190 of 383) with videos related to

Sort By:
Pageof 39
Breast (Edinburgh, Scotland)|February 19, 2013
Triple negative breast cancer: clinical characteristics in the different histological subtypesGeertje Dreyer, Thijs Vandorpe, Ann Smeets, et al.
Plos One|March 4, 2014
A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samplesMelike Marsan, Gert Van den Eynden, Ridha Limame, et al.
Radiology and Oncology|January 23, 2020
Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot studyBrigitte Maximiliana Aarts, Elisabeth Geneviève Klompenhouwer, Raphaëla Carmen Dresen, et al.
Plos One|April 6, 2012
A mathematical model for interpretable clinical decision support with applications in gynecologyVanya M C A Van Belle, Ben Van Calster, Dirk Timmerman, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2015
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08Khalil Zaman, Ralph Winterhalder, Christoph Mamot, et al.
The Breast Journal|November 13, 2010
Additional value of PET-CT in staging of clinical stage IIB and III breast cancerIsabelle Segaert, Felix Mottaghy, Sarah Ceyssens, et al.
Breast Cancer Research : BCR|August 24, 2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, Hope S Rugo, Sara M Tolaney, et al.
Obstetrics and Gynecology|May 4, 2004
Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX studyPatrick Neven, Deborah Quail, Marc Lévrier, et al.
BMC Medical Genomics|July 4, 2009
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trialChristine Desmedt, Anita Giobbie-Hurder, Patrick Neven, et al.
BMC Pharmacology & Toxicology|April 17, 2015
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerSandrina Lambrechts, Diether Lambrechts, Evelyn Despierre, et al.
Pageof 39